The MVA component of our vaccine has the potential to protect humans against smallpox as well as AIDS.
MVA non human (primate) trials completed by Dr. Bernard Moss at the NIH in 2004 confirmed MVA as highly protective against smallpox virus challenge. MVA is an attenuated form of a smallpox virus that was developed near the end of the smallpox eradication program in Germany during the 1970's for use in immuno-compromised humans. Given that current conventional smallpox vaccines have a high incidence of side effects, MVA has re-emerged as a promising vaccine candidate for protection against smallpox vaccine as it appears safer than current smallpox vaccines.
Protecting against AIDS and smallpox would be a tremendous competitive as well as health advantage our vaccine may provide. However, additional studies will need to be conducted to prove MVA is broadly effective against smallpox.